サマリー

市場分析と洞察。ジェネリックおよびバイオシミラー医薬品の世界市場
2020年のジェネリック医薬品とバイオシミラー医薬品の世界市場規模はXX百万米ドルで、2021年から2027年の間にXX％のCAGRで、2027年末にはXX百万米ドルに達すると予想されています。

世界のジェネリック・バイオシミラー医薬品の範囲と市場規模
ジェネリックおよびバイオシミラー医薬品市場は、企業別、地域（国）別、タイプ別、アプリケーション別に分類されています。世界のジェネリック医薬品・バイオシミラー医薬品市場のプレイヤー、ステークホルダー、その他の参加者は、本レポートを強力なリソースとして活用することで、優位に立つことができるでしょう。セグメント別分析では、2016年から2027年までの市場規模と予測に焦点を当てています。
Segment by Type, Generic and Biosimilar Pharmaceuticals market is segmented into Monoclonal Antibodies, Interferon, Erythropoietin, Insulin, Vaccine, Other, etc....
用途別では、ジェネリック医薬品・バイオシミラー医薬品市場は、腫瘍、糖尿病、心血管、血友病、その他などに分類されます。

地域・国別分析
当レポートでは、米国、カナダ、ドイツ、フランス、英国、イタリア、ロシア、中国、日本、韓国、台湾、インド、オーストラリア、インドネシア、タイ、マレーシア、フィリピン、ベトナム、メキシコ、ブラジル、アルゼンチン、サウジアラビア、アラブ首長国連邦、トルコなどの地域別・国別のジェネリック医薬品・バイオシミラー医薬品市場を網羅的に評価しています。
本レポートでは、2016-2027年の期間において、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカの国（地域）別、タイプ別、アプリケーション別の市場規模、およびプレイヤー別の市場規模を掲載しています。

競合状況とジェネリックおよびバイオシミラー医薬品市場シェア分析
ジェネリックおよびバイオシミラー医薬品市場の競合状況は、ベンダーによる詳細およびデータ情報を提供しています。2016年から2021年の期間、プレイヤーによる収益の包括的な分析と正確な統計を提供しています。また、2016年から2021年の期間におけるプレイヤー別の収益（世界および地域レベル）について、信頼性の高い統計に支えられた詳細な分析を提供しています。含まれる詳細は、会社概要、主要事業、会社の総収入とジェネリックおよびバイオシミラー医薬品事業で得た収入、ジェネリックおよびバイオシミラー医薬品市場への参入日、ジェネリックおよびバイオシミラー医薬品の製品紹介、最近の開発状況などです。
主要ベンダーとしては、ロシュ、アムジェン、アッヴィ、サノフィ・アベンティス、ジョンソン・エンド・ジョンソン、ファイザー、ノボ・ノルディスク、イーライ・リリー、ノバルティス、メルク、3sbio、Changchun High Tech、CP Guojian、Biotech、Gelgen、Innovent、Dong Bao、Ganleeなどが挙げられます。

ページTOPに戻る

目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Generic and Biosimilar Pharmaceuticals Market Size by Type: 2016 VS 2021 VS 2027
1.2.2 Monoclonal Antibodies
1.2.3 Interferon
1.2.4 Erythropoietin
1.2.5 Insulin
1.2.6 Vaccines
1.2.7 Other
1.3 Market by Application
1.3.1 Global Generic and Biosimilar Pharmaceuticals Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Tumor
1.3.3 Diabetes
1.3.4 Cardiovascular
1.3.5 Hemophilia
1.3.6 Other
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trend
2.1 Global Generic and Biosimilar Pharmaceuticals Market Perspective (2016-2027)
2.2 Global Generic and Biosimilar Pharmaceuticals Growth Trends by Regions
2.2.1 Generic and Biosimilar Pharmaceuticals Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Generic and Biosimilar Pharmaceuticals Historic Market Size by Regions (2016-2021)
2.2.3 Generic and Biosimilar Pharmaceuticals Forecasted Market Size by Regions (2022-2027)
2.3 Industry Trends and Growth Strategy
2.3.1 Generic and Biosimilar Pharmaceuticals Industry Trends
2.3.2 Generic and Biosimilar Pharmaceuticals Market Drivers
2.3.3 Generic and Biosimilar Pharmaceuticals Market Challenges
2.3.4 Generic and Biosimilar Pharmaceuticals Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Generic and Biosimilar Pharmaceuticals Players by Market Size
3.1.1 Players Covered: Ranking by Generic and Biosimilar Pharmaceuticals Revenue
3.1.2 Global Top Generic and Biosimilar Pharmaceuticals Players by Revenue (2016-2021)
3.1.3 Global Generic and Biosimilar Pharmaceuticals Revenue Market Share by Players (2016-2021)
3.1.4 Global Generic and Biosimilar Pharmaceuticals Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Generic and Biosimilar Pharmaceuticals Market Concentration Ratio
3.2.1 Global Generic and Biosimilar Pharmaceuticals Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 5 and Top 10 Players by Generic and Biosimilar Pharmaceuticals Revenue in 2020
3.3 Generic and Biosimilar Pharmaceuticals Key Players Head office and Area Served
3.4 Key Players Generic and Biosimilar Pharmaceuticals Product Solution and Service
3.5 Date of Enter into Generic and Biosimilar Pharmaceuticals Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Global Generic and Biosimilar Pharmaceuticals Breakdown Data by Type (2016-2027)
4.1 Global Generic and Biosimilar Pharmaceuticals Historic Market Size by Type (2016-2021)
4.2 Global Generic and Biosimilar Pharmaceuticals Forecasted Market Size by Type (2022-2027)

5 Global Generic and Biosimilar Pharmaceuticals Breakdown Data by Application (2016-2027)
5.1 Global Generic and Biosimilar Pharmaceuticals Historic Market Size by Application (2016-2021)
5.2 Generic and Biosimilar Pharmaceuticals Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Generic and Biosimilar Pharmaceuticals Market Size (2016-2027)
6.2 Key Generic and Biosimilar Pharmaceuticals Players Market Share in North America (2020-2021)
6.3 North America Generic and Biosimilar Pharmaceuticals Market Size by Country
6.3.1 North America Generic and Biosimilar Pharmaceuticals Market Size by Country (2016-2021)
6.3.2 North America Generic and Biosimilar Pharmaceuticals Market Size Forecast by Country (2022-2027)
6.4 U.S. Market Size Analysis
6.4.1 U.S. Generic and Biosimilar Pharmaceuticals Market Size (2016-2027)
6.4.2 U.S. Generic and Biosimilar Pharmaceuticals Market Size by Type (2016-2027)
6.4.3 U.S. Generic and Biosimilar Pharmaceuticals Market Size by Application (2016-2027)
6.5 Canada Market Size Analysis
6.5.1 Canada Generic and Biosimilar Pharmaceuticals Market Size (2016-2027)
6.5.2 Canada Generic and Biosimilar Pharmaceuticals Market Size by Type (2016-2027)
6.5.3 Canada Generic and Biosimilar Pharmaceuticals Market Size by Application (2016-2027)

7 Europe
7.1 Europe Generic and Biosimilar Pharmaceuticals Market Size (2016-2027)
7.2 Key Generic and Biosimilar Pharmaceuticals Players Market Share in Europe (2020-2021)
7.3 Europe Generic and Biosimilar Pharmaceuticals Market Size by Country
7.3.1 Europe Generic and Biosimilar Pharmaceuticals Market Size by Country (2016-2021)
7.3.2 Europe Generic and Biosimilar Pharmaceuticals Market Size Forecast by Country (2022-2027)
7.4 Germany Market Size Analysis
7.4.1 Germany Generic and Biosimilar Pharmaceuticals Market Size (2016-2027)
7.4.2 Germany Generic and Biosimilar Pharmaceuticals Market Size by Type (2016-2027)
7.4.3 Germany Generic and Biosimilar Pharmaceuticals Market Size by Application (2016-2027)
7.5 France Market Size Analysis
7.5.1 France Generic and Biosimilar Pharmaceuticals Market Size (2016-2027)
7.5.2 France Generic and Biosimilar Pharmaceuticals Market Size by Type (2016-2027)
7.5.3 France Generic and Biosimilar Pharmaceuticals Market Size by Application (2016-2027)
7.6 U.K. Market Size Analysis
7.6.1 U.K. Generic and Biosimilar Pharmaceuticals Market Size (2016-2027)
7.6.2 U.K. Generic and Biosimilar Pharmaceuticals Market Size by Type (2016-2027)
7.6.3 U.K. Generic and Biosimilar Pharmaceuticals Market Size by Application (2016-2027)
7.7 Italy Market Size Analysis
7.7.1 Italy Generic and Biosimilar Pharmaceuticals Market Size (2016-2027)
7.7.2 Italy Generic and Biosimilar Pharmaceuticals Market Size by Type (2016-2027)
7.7.3 Italy Generic and Biosimilar Pharmaceuticals Market Size by Application (2016-2027)
7.8 Russia Market Size Analysis
7.8.1 Russia Generic and Biosimilar Pharmaceuticals Market Size (2016-2027)
7.8.2 Russia Generic and Biosimilar Pharmaceuticals Market Size by Type (2016-2027)
7.8.3 Russia Generic and Biosimilar Pharmaceuticals Market Size by Application (2016-2027)

8 Asia-Pacific
8.1 Asia-Pacific Generic and Biosimilar Pharmaceuticals Market Size (2016-2027)
8.2 Key Generic and Biosimilar Pharmaceuticals Players Market Share in Asia-Pacific (2020-2021)
8.3 Asia-Pacific Generic and Biosimilar Pharmaceuticals Market Size by Region
8.3.1 Asia-Pacific Generic and Biosimilar Pharmaceuticals Market Size by Region (2016-2021)
8.3.2 Asia-Pacific Generic and Biosimilar Pharmaceuticals Market Size Forecast by Region (2022-2027)
8.4 China Market Size Analysis
8.4.1 China Generic and Biosimilar Pharmaceuticals Market Size (2016-2027)
8.4.2 China Generic and Biosimilar Pharmaceuticals Market Size by Type (2016-2027)
8.4.3 China Generic and Biosimilar Pharmaceuticals Market Size by Application (2016-2027)
8.5 Japan Market Size Analysis
8.5.1 Japan Generic and Biosimilar Pharmaceuticals Market Size (2016-2027)
8.5.2 Japan Generic and Biosimilar Pharmaceuticals Market Size by Type (2016-2027)
8.5.3 Japan Generic and Biosimilar Pharmaceuticals Market Size by Application (2016-2027)
8.6 South Korea Market Size Analysis
8.6.1 South Korea Generic and Biosimilar Pharmaceuticals Market Size (2016-2027)
8.6.2 South Korea Generic and Biosimilar Pharmaceuticals Market Size by Type (2016-2027)
8.6.3 South Korea Generic and Biosimilar Pharmaceuticals Market Size by Application (2016-2027)
8.7 India Market Size Analysis
8.7.1 India Generic and Biosimilar Pharmaceuticals Market Size (2016-2027)
8.7.2 India Generic and Biosimilar Pharmaceuticals Market Size by Type (2016-2027)
8.7.3 India Generic and Biosimilar Pharmaceuticals Market Size by Application (2016-2027)
8.8 Australia Market Size Analysis
8.8.1 Australia Generic and Biosimilar Pharmaceuticals Market Size (2016-2027)
8.8.2 Australia Generic and Biosimilar Pharmaceuticals Market Size by Type (2016-2027)
8.8.3 Australia Generic and Biosimilar Pharmaceuticals Market Size by Application (2016-2027)
8.9 Taiwan Market Size Analysis
8.9.1 Taiwan Generic and Biosimilar Pharmaceuticals Market Size (2016-2027)
8.9.2 Taiwan Generic and Biosimilar Pharmaceuticals Market Size by Type (2016-2027)
8.9.3 Taiwan Generic and Biosimilar Pharmaceuticals Market Size by Application (2016-2027)
8.10 Indonesia Market Size Analysis
8.10.1 Indonesia Generic and Biosimilar Pharmaceuticals Market Size (2016-2027)
8.10.2 Indonesia Generic and Biosimilar Pharmaceuticals Market Size by Type (2016-2027)
8.10.3 Indonesia Generic and Biosimilar Pharmaceuticals Market Size by Application (2016-2027)
8.11 Thailand Market Size Analysis
8.11.1 Thailand Generic and Biosimilar Pharmaceuticals Market Size (2016-2027)
8.11.2 Thailand Generic and Biosimilar Pharmaceuticals Market Size by Type (2016-2027)
8.11.3 Thailand Generic and Biosimilar Pharmaceuticals Market Size by Application (2016-2027)
8.12 Malaysia Market Size Analysis
8.12.1 Malaysia Generic and Biosimilar Pharmaceuticals Market Size (2016-2027)
8.12.2 Malaysia Generic and Biosimilar Pharmaceuticals Market Size by Type (2016-2027)
8.12.3 Malaysia Generic and Biosimilar Pharmaceuticals Market Size by Application (2016-2027)
8.13 Philippines Market Size Analysis
8.13.1 Philippines Generic and Biosimilar Pharmaceuticals Market Size (2016-2027)
8.13.2 Philippines Generic and Biosimilar Pharmaceuticals Market Size by Type (2016-2027)
8.13.3 Philippines Generic and Biosimilar Pharmaceuticals Market Size by Application (2016-2027)
8.14 Vietnam Market Size Analysis
8.14.1 Vietnam Generic and Biosimilar Pharmaceuticals Market Size (2016-2027)
8.14.2 Vietnam Generic and Biosimilar Pharmaceuticals Market Size by Type (2016-2027)
8.14.3 Vietnam Generic and Biosimilar Pharmaceuticals Market Size by Application (2016-2027)

9 Latin America
9.1 Latin America Generic and Biosimilar Pharmaceuticals Market Size (2016-2027)
9.2 Key Generic and Biosimilar Pharmaceuticals Players Market Share in Latin America (2020-2021)
9.3 Latin America Generic and Biosimilar Pharmaceuticals Market Size by Country
9.3.1 Latin America Generic and Biosimilar Pharmaceuticals Market Size by Country (2016-2021)
9.3.2 Latin America Generic and Biosimilar Pharmaceuticals Market Size Forecast by Country (2022-2027)
9.4 Mexico Market Size Analysis
9.4.1 Mexico Generic and Biosimilar Pharmaceuticals Market Size (2016-2027)
9.4.2 Mexico Generic and Biosimilar Pharmaceuticals Market Size by Type (2016-2027)
9.4.3 Mexico Generic and Biosimilar Pharmaceuticals Market Size by Application (2016-2027)
9.5 Brazil Market Size Analysis
9.5.1 Brazil Generic and Biosimilar Pharmaceuticals Market Size (2016-2027)
9.5.2 Brazil Generic and Biosimilar Pharmaceuticals Market Size by Type (2016-2027)
9.5.3 Brazil Generic and Biosimilar Pharmaceuticals Market Size by Application (2016-2027)
9.6 Argentina Market Size Analysis
9.6.1 Argentina Generic and Biosimilar Pharmaceuticals Market Size (2016-2027)
9.6.2 Argentina Generic and Biosimilar Pharmaceuticals Market Size by Type (2016-2027)
9.6.3 Argentina Generic and Biosimilar Pharmaceuticals Market Size by Application (2016-2027)

10 Middle East & Africa
10.1 Middle East & Africa Generic and Biosimilar Pharmaceuticals Market Size (2016-2027)
10.2 Key Generic and Biosimilar Pharmaceuticals Players Market Share in Middle East & Africa (2020-2021)
10.3 Middle East & Africa Generic and Biosimilar Pharmaceuticals Market Size by Country
10.3.1 Middle East & Africa Generic and Biosimilar Pharmaceuticals Market Size by Country (2016-2021)
10.3.2 Middle East & Africa Generic and Biosimilar Pharmaceuticals Market Size Forecast by Country (2022-2027)
10.4 Turkey Market Size Analysis
10.4.1 Turkey Generic and Biosimilar Pharmaceuticals Market Size (2016-2027)
10.4.2 Turkey Generic and Biosimilar Pharmaceuticals Market Size by Type (2016-2027)
10.4.3 Turkey Generic and Biosimilar Pharmaceuticals Market Size by Application (2016-2027)
10.5 Saudi Arabia Market Size Analysis
10.5.1 Saudi Arabia Generic and Biosimilar Pharmaceuticals Market Size (2016-2027)
10.5.2 Saudi Arabia Generic and Biosimilar Pharmaceuticals Market Size by Type (2016-2027)
10.5.3 Saudi Arabia Generic and Biosimilar Pharmaceuticals Market Size by Application (2016-2027)
10.6 UAE Market Size Analysis
10.6.1 UAE Generic and Biosimilar Pharmaceuticals Market Size (2016-2027)
10.6.2 UAE Generic and Biosimilar Pharmaceuticals Market Size by Type (2016-2027)
10.6.3 UAE Generic and Biosimilar Pharmaceuticals Market Size by Application (2016-2027)

11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview and Its Total Revenue
11.1.3 Roche Generic and Biosimilar Pharmaceuticals Introduction
11.1.4 Roche Revenue in Generic and Biosimilar Pharmaceuticals Business (2016-2021)
11.1.5 Roche Recent Development
11.2 Amgen
11.2.1 Amgen Company Details
11.2.2 Amgen Business Overview and Its Total Revenue
11.2.3 Amgen Generic and Biosimilar Pharmaceuticals Introduction
11.2.4 Amgen Revenue in Generic and Biosimilar Pharmaceuticals Business (2016-2021)
11.2.5 Amgen Recent Development
11.3 AbbVie
11.3.1 AbbVie Company Details
11.3.2 AbbVie Business Overview and Its Total Revenue
11.3.3 AbbVie Generic and Biosimilar Pharmaceuticals Introduction
11.3.4 AbbVie Revenue in Generic and Biosimilar Pharmaceuticals Business (2016-2021)
11.3.5 AbbVie Recent Development
11.4 Sanofi-Aventis
11.4.1 Sanofi-Aventis Company Details
11.4.2 Sanofi-Aventis Business Overview and Its Total Revenue
11.4.3 Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Introduction
11.4.4 Sanofi-Aventis Revenue in Generic and Biosimilar Pharmaceuticals Business (2016-2021)
11.4.5 Sanofi-Aventis Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Details
11.5.2 Johnson & Johnson Business Overview and Its Total Revenue
11.5.3 Johnson & Johnson Generic and Biosimilar Pharmaceuticals Introduction
11.5.4 Johnson & Johnson Revenue in Generic and Biosimilar Pharmaceuticals Business (2016-2021)
11.5.5 Johnson & Johnson Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Details
11.6.2 Pfizer Business Overview and Its Total Revenue
11.6.3 Pfizer Generic and Biosimilar Pharmaceuticals Introduction
11.6.4 Pfizer Revenue in Generic and Biosimilar Pharmaceuticals Business (2016-2021)
11.6.5 Pfizer Recent Development
11.7 Novo Nordisk
11.7.1 Novo Nordisk Company Details
11.7.2 Novo Nordisk Business Overview and Its Total Revenue
11.7.3 Novo Nordisk Generic and Biosimilar Pharmaceuticals Introduction
11.7.4 Novo Nordisk Revenue in Generic and Biosimilar Pharmaceuticals Business (2016-2021)
11.7.5 Novo Nordisk Recent Development
11.8 Eli Lilly
11.8.1 Eli Lilly Company Details
11.8.2 Eli Lilly Business Overview and Its Total Revenue
11.8.3 Eli Lilly Generic and Biosimilar Pharmaceuticals Introduction
11.8.4 Eli Lilly Revenue in Generic and Biosimilar Pharmaceuticals Business (2016-2021)
11.8.5 Eli Lilly Recent Development
11.9 Novartis
11.9.1 Novartis Company Details
11.9.2 Novartis Business Overview and Its Total Revenue
11.9.3 Novartis Generic and Biosimilar Pharmaceuticals Introduction
11.9.4 Novartis Revenue in Generic and Biosimilar Pharmaceuticals Business (2016-2021)
11.9.5 Novartis Recent Development
11.10 Merck
11.10.1 Merck Company Details
11.10.2 Merck Business Overview and Its Total Revenue
11.10.3 Merck Generic and Biosimilar Pharmaceuticals Introduction
11.10.4 Merck Revenue in Generic and Biosimilar Pharmaceuticals Business (2016-2021)
11.10.5 Merck Recent Development
11.11 3sbio
11.11.1 3sbio Company Details
11.11.2 3sbio Business Overview and Its Total Revenue
11.11.3 3sbio Generic and Biosimilar Pharmaceuticals Introduction
11.11.4 3sbio Revenue in Generic and Biosimilar Pharmaceuticals Business (2016-2021)
11.11.5 3sbio Recent Development
11.12 Changchun High Tech
11.12.1 Changchun High Tech Company Details
11.12.2 Changchun High Tech Business Overview and Its Total Revenue
11.12.3 Changchun High Tech Generic and Biosimilar Pharmaceuticals Introduction
11.12.4 Changchun High Tech Revenue in Generic and Biosimilar Pharmaceuticals Business (2016-2021)
11.12.5 Changchun High Tech Recent Development
11.13 CP Guojian
11.13.1 CP Guojian Company Details
11.13.2 CP Guojian Business Overview and Its Total Revenue
11.13.3 CP Guojian Generic and Biosimilar Pharmaceuticals Introduction
11.13.4 CP Guojian Revenue in Generic and Biosimilar Pharmaceuticals Business (2016-2021)
11.13.5 CP Guojian Recent Development
11.14 Biotech
11.14.1 Biotech Company Details
11.14.2 Biotech Business Overview and Its Total Revenue
11.14.3 Biotech Generic and Biosimilar Pharmaceuticals Introduction
11.14.4 Biotech Revenue in Generic and Biosimilar Pharmaceuticals Business (2016-2021)
11.14.5 Biotech Recent Development
11.15 Gelgen
11.15.1 Gelgen Company Details
11.15.2 Gelgen Business Overview and Its Total Revenue
11.15.3 Gelgen Generic and Biosimilar Pharmaceuticals Introduction
11.15.4 Gelgen Revenue in Generic and Biosimilar Pharmaceuticals Business (2016-2021)
11.15.5 Gelgen Recent Development
11.16 Innovent
11.16.1 Innovent Company Details
11.16.2 Innovent Business Overview and Its Total Revenue
11.16.3 Innovent Generic and Biosimilar Pharmaceuticals Introduction
11.16.4 Innovent Revenue in Generic and Biosimilar Pharmaceuticals Business (2016-2021)
11.16.5 Innovent Recent Development
11.17 Dong Bao
11.17.1 Dong Bao Company Details
11.17.2 Dong Bao Business Overview and Its Total Revenue
11.17.3 Dong Bao Generic and Biosimilar Pharmaceuticals Introduction
11.17.4 Dong Bao Revenue in Generic and Biosimilar Pharmaceuticals Business (2016-2021)
11.17.5 Dong Bao Recent Development
11.18 Ganlee
11.18.1 Ganlee Company Details
11.18.2 Ganlee Business Overview and Its Total Revenue
11.18.3 Ganlee Generic and Biosimilar Pharmaceuticals Introduction
11.18.4 Ganlee Revenue in Generic and Biosimilar Pharmaceuticals Business (2016-2021)
11.18.5 Ganlee Recent Development

12 Analyst's Viewpoints/Conclusion

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details